Vilon (KE)

What is Vilon?

Vilon is a synthetic dipeptide — just two amino acids: lysine-glutamic acid (Lys-Glu, abbreviated KE). Developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, it is the Cytogen (synthetic sequence) form of the thymus bioregulator system. Where Thymalin is the full natural thymic extract (Cytomax), Vilon is the isolated active dipeptide.

The thymus is ground zero for immune aging. It involutes progressively from your 20s — the thymic tissue that produces T-cells is steadily replaced by fat and connective tissue. By age 50, most people have lost the majority of functional thymic tissue. This thymic involution is one of the most reproducible features of biological aging, correlating directly with declining immune competence, reduced resistance to infection, and increased cancer risk.

Vilon's proposed role is to send a direct signal — at the chromatin level — that counteracts this decline. Khavinson's group characterizes it as a gene expression regulator for thymic tissue, capable of promoting T-cell maturation and interleukin production in aged immune systems.

How it works

Chromatin Interaction, Not Receptor Binding

Like all Khavinson Cytogens, Vilon is hypothesized to work epigenetically. The peptide penetrates cell nuclei and interacts with DNA-histone complexes, influencing gene expression in thymic tissue specifically. This differs from most peptides, which bind surface receptors. The chromatin interaction model predicts tissue-specific effects — which is what the available evidence suggests.

Interleukin Modulation

Cell studies show Vilon modulates interleukin-2 (IL-2) production — a key T-cell growth factor — and upregulates interferon-gamma in lymphocytes. These are the cytokines most directly involved in T-cell proliferation and activation. In aged animals with reduced IL-2 production, Vilon restored IL-2 levels toward younger profiles.

T-Cell Maturation

Khavinson's group reported that Vilon promotes differentiation and maturation of T-lymphocytes — supporting the conversion of immature thymocytes to functional mature T-cells. This is the core mechanism proposed for its immune-restorative effects.

What the research shows

Community knowledge

Vilon is moderately popular in longevity biohacker circles, primarily as the injectable Cytogen counterpart to Thymalin. It frequently appears in the same stack — a Thymalin course followed by Vilon maintenance, or both run simultaneously. Reports focus on subjective improvements in immune resilience (fewer infections, faster recovery), energy, and general wellbeing over 3–6 month windows.

Because Vilon is a dipeptide (smaller than most Cytogens), some researchers suggest superior tissue penetration. This is theoretical — not established in controlled studies. The practical observation is that it is well-tolerated with a low side-effect profile consistent with other Khavinson short peptides.